What is Stoke Therapeutics, Inc.'s change in deferred revenue?

Stoke Therapeutics, Inc. (STOK) reported change in deferred revenue of -$2.19M in Q1 2026.

How has Stoke Therapeutics, Inc.'s change in deferred revenue changed year-over-year?

Stoke Therapeutics, Inc.'s change in deferred revenue decreased by 123.3% year-over-year, from $9.43M to -$2.19M.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Stoke Therapeutics, Inc. STOK Change in Deferred Revenue

Change in Deferred Revenue at other companies

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

Nurix Therapeutics, Inc.NRIX

-$1.25M+87.3%

Sarepta Therapeutics, Inc.SRPT

-$274.92M-222%

Tango TherapeuticsTNGX

$0+100%

Septerna, Inc.SEPN

-$16.24M-139%

IDEAYA Biosciences, Inc.IDYA

-$587K—

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s change in deferred revenue?: Stoke Therapeutics, Inc. (STOK) reported change in deferred revenue of -$2.19M in Q1 2026.
How has Stoke Therapeutics, Inc.'s change in deferred revenue changed year-over-year?: Stoke Therapeutics, Inc.'s change in deferred revenue decreased by 123.3% year-over-year, from $9.43M to -$2.19M.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.